BetterLife Pharma Inc. announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001's repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0906 USD | +3.84% | -5.82% | +88.75% |
05-03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
05-01 | BetterLife Pharma Advances IND-enabling Studies For BETR-001 | MT |
1st Jan change | Capi. | |
---|---|---|
+88.75% | 10.12M | |
+5.02% | 111B | |
+10.90% | 105B | |
-12.35% | 22.34B | |
-3.26% | 21.93B | |
-5.75% | 18.59B | |
-36.52% | 18.12B | |
-9.51% | 16.96B | |
+3.64% | 13.7B | |
+37.05% | 12.45B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001